Today, Concord Biotech Limited made its debut on the stock markets by going public at Rs 900 per share, 21.46% higher than its IPO price of Rs 741. Concord Biotech is a leading API company with a proven track record. The company manufactures and exports APIs for a wide range of therapeutic areas. However, the company's international operations expose it to various complex risks. Additionally, this industry has been facing margin pressure recently. Overall, the listing of Concord Biotech was in line with expectations. The company's strong fundamentals and good subscription levels were positive factors for this. Investors who participated in the IPO should consider booking profits post-listing,said Anubhuti Mishra Research Analyst at Swastika Investmart.Read more:
